BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...Ltd. $97.4 Carrick Therapeutics Ltd. $95.0 Northwest Biotherapeutics Inc. (OTCQB:NWBO) $95.0 Mission Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc....
BioCentury | Nov 11, 2019
Emerging Company Profile

Mycovia tackling chronic infections with antifungal pipeline

...Analysts estimate VT-1161 could have worldwide sales of up to $700 million. VT-1161 originated at Viamet Pharmaceuticals Inc....
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...Ltd. $97.4 Carrick Therapeutics Ltd. $95.0 Northwest Biotherapeutics Inc. (OTCQB:NWBO) $95.0 Mission Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc....
BioCentury | Oct 30, 2017
Company News

Management Tracks: Biohaven, Selecta

...hired Amir Tavakkol as EVP and chief development officer. He was chief development officer at Viamet Pharmaceuticals Inc....
BioCentury | Jan 13, 2017
Clinical News

VT-1161: Additional Ph IIb REVIVE data

...Viamet has previously reported interim data from the trial (see BioCentury, March 14, 2016 ). Viamet Pharmaceuticals Inc....
...culture-verified acute vulvovaginal candidiasis infection through week 48 Status: Additional Phase IIb data Milestone: NA Julian Zhu VT-1161 Viamet Pharmaceuticals Inc. Cytochrome...
BioCentury | Jan 13, 2017
Clinical News

VT-1161: Additional Ph IIb RENOVATE data

...Viamet has previously reported interim data from the trial (see BioCentury, March 14, 2016 ). Viamet Pharmaceuticals Inc....
...KOH and negative dermatophyte culture), at week 48 Status: Additional Phase IIb data Milestone: NA Julian Zhu VT-1161 Viamet Pharmaceuticals Inc. Cytochrome...
BioCentury | Oct 17, 2016
Clinical News

VT-1161 regulatory update

...FDA granted Qualified Infectious Disease Product (QIDP) designation to VT-1161 from Viamet to treat recurrent vulvovaginal...
...alpha demethylase (CYP51) , which blocks production of ergosterol , a fungal cell wall component. Viamet Pharmaceuticals Inc....
BioCentury | Sep 19, 2016
Clinical News

VT-1598 regulatory update

...FDA granted Qualified Infectious Disease Product (QIDP) designation to VT-1598 from Viamet to treat coccidioidomycosis (valley...
...The compound is an oral inhibitor of fungal cytochrome P450 C-14 alpha demethylase (CYP51) . Viamet Pharmaceuticals Inc....
BioCentury | Aug 22, 2016
Emerging Company Profile

Metal smithing

...A2A's program, citing unfamiliarity. At least one other company has developed a metalloenzyme inhibitor platform. Viamet...
...less promiscuous metal-binding moieties, then uses computational design to optimize the original backbone for potency. Viamet's...
...Forge Therapeutics Inc., San Diego, Calif. University of California San Diego , La Jolla, Calif. Viamet Pharmaceuticals Inc....
BioCentury | Jul 13, 2016
Company News

Management tracks

...NASDAQ:NBRV). Oncology company Argos Therapeutics Inc. (NASDAQ:ARGS) named Richard Katz CFO. He was CFO at Viamet Pharmaceuticals Inc....
Items per page:
1 - 10 of 55
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...Ltd. $97.4 Carrick Therapeutics Ltd. $95.0 Northwest Biotherapeutics Inc. (OTCQB:NWBO) $95.0 Mission Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc....
BioCentury | Nov 11, 2019
Emerging Company Profile

Mycovia tackling chronic infections with antifungal pipeline

...Analysts estimate VT-1161 could have worldwide sales of up to $700 million. VT-1161 originated at Viamet Pharmaceuticals Inc....
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...Ltd. $97.4 Carrick Therapeutics Ltd. $95.0 Northwest Biotherapeutics Inc. (OTCQB:NWBO) $95.0 Mission Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc....
BioCentury | Oct 30, 2017
Company News

Management Tracks: Biohaven, Selecta

...hired Amir Tavakkol as EVP and chief development officer. He was chief development officer at Viamet Pharmaceuticals Inc....
BioCentury | Jan 13, 2017
Clinical News

VT-1161: Additional Ph IIb REVIVE data

...Viamet has previously reported interim data from the trial (see BioCentury, March 14, 2016 ). Viamet Pharmaceuticals Inc....
...culture-verified acute vulvovaginal candidiasis infection through week 48 Status: Additional Phase IIb data Milestone: NA Julian Zhu VT-1161 Viamet Pharmaceuticals Inc. Cytochrome...
BioCentury | Jan 13, 2017
Clinical News

VT-1161: Additional Ph IIb RENOVATE data

...Viamet has previously reported interim data from the trial (see BioCentury, March 14, 2016 ). Viamet Pharmaceuticals Inc....
...KOH and negative dermatophyte culture), at week 48 Status: Additional Phase IIb data Milestone: NA Julian Zhu VT-1161 Viamet Pharmaceuticals Inc. Cytochrome...
BioCentury | Oct 17, 2016
Clinical News

VT-1161 regulatory update

...FDA granted Qualified Infectious Disease Product (QIDP) designation to VT-1161 from Viamet to treat recurrent vulvovaginal...
...alpha demethylase (CYP51) , which blocks production of ergosterol , a fungal cell wall component. Viamet Pharmaceuticals Inc....
BioCentury | Sep 19, 2016
Clinical News

VT-1598 regulatory update

...FDA granted Qualified Infectious Disease Product (QIDP) designation to VT-1598 from Viamet to treat coccidioidomycosis (valley...
...The compound is an oral inhibitor of fungal cytochrome P450 C-14 alpha demethylase (CYP51) . Viamet Pharmaceuticals Inc....
BioCentury | Aug 22, 2016
Emerging Company Profile

Metal smithing

...A2A's program, citing unfamiliarity. At least one other company has developed a metalloenzyme inhibitor platform. Viamet...
...less promiscuous metal-binding moieties, then uses computational design to optimize the original backbone for potency. Viamet's...
...Forge Therapeutics Inc., San Diego, Calif. University of California San Diego , La Jolla, Calif. Viamet Pharmaceuticals Inc....
BioCentury | Jul 13, 2016
Company News

Management tracks

...NASDAQ:NBRV). Oncology company Argos Therapeutics Inc. (NASDAQ:ARGS) named Richard Katz CFO. He was CFO at Viamet Pharmaceuticals Inc....
Items per page:
1 - 10 of 55